Venous thromboembolism - dabigatran: final appraisal determination
After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination (FAD) on Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults and submitted it to the Institute.
The FAD has been sent to the formal consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it. Subject to any appeal by consultees, the FAD may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England and Wales.
Please note that the appeal period for this appraisal will close at 5pm on 11th August 2008.
Venous thromboembolism - dabigatran: final appraisal determination
Venous thromboembolism - dabigatran: evaluation report
Venous thromboembolism - dabigatran: non-manufacturer submissions
Venous thromboembolism - dabigatran: manufacturer submission
Venous thromboembolism - dabigatran: clarification letters
Venous thromboembolism - dabigatran: expert written personal statements
This page was last updated: 30 March 2010